Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;28(6):791-796.
doi: 10.1016/j.jiac.2022.02.020. Epub 2022 Mar 1.

Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers

Affiliations

Adverse effect investigation using application software after vaccination against SARS-CoV-2 for healthcare workers

Shingo Yamazaki et al. J Infect Chemother. 2022 Jun.

Abstract

Introduction: The usefulness of smartphone-based application software as a way to manage adverse events (AEs) after vaccination is well known. The purpose of this study is to clarify the usefulness and precautions of employing a smartphone application for collecting AEs after the administration of Comirnaty®️.

Methods: Healthcare workers (HCWs) who were vaccinated with Comirnaty®️ were asked to register for the application software and to report AEs for 14 days after vaccination. AEs were self-reported according to severity. The software was set to output an alert in case of fever.

Results: The number of HCWs who received the first dose was 2,551, and 2,406 (94.3%) reported their vaccinations. 2,547 received the second dose, and 2,347 (92.1%) reported their vaccinations. With the first dose, the reporting rate stayed above 83.3% until the final day. On the other hand, that of the second dose decreased rapidly after 6 days. The most frequent symptom was "pain at injection site" (more than 70%). Severe AEs were 6.6% after the second dose, with 0.6% visiting a clinic. Many AEs peaked on the day after administration and disappeared within 1 week. There were few reports of fever.

Conclusion: Smartphone applications can be used to collect information on AEs after vaccination. Application settings and dissemination are necessary to maintain the reporting rate of HCWs.

Keywords: Adverse event; Application software; SARS-CoV2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Taka-aki Nakada (TN) is an inventor and has submitted patents related to respon:sum system. TN serves as CEO, receives executive compensation and holds shares in Smart119 Inc., which develops the respon:sum system.

Figures

Fig. 1
Fig. 1
Changes in health status reporting rate The black and gray lines indicate the reporting rates after the first and second doses, respectively.
Fig. 2
Fig. 2
Classification of adverse events by age The severity of adverse events during the study period after vaccination is shown by age. HCWs, health care workers.
Fig. 3
Fig. 3
Ratio of HCWs reporting adverse events and the day after vaccination HCWs, health care workers.

Similar articles

Cited by

References

    1. Alencar C.H., Cavalcanti L.P.G., Almeida M.M., Barbosa P.P.L., Cavalcante K.K.S., Melo D.N., et al. High effectiveness of SARS-CoV-2 vaccines in reducing COVID-19-related deaths in over 75-year-olds, ceara state, Brazil. Trav Med Infect Dis. 2021;6:129. - PMC - PubMed
    1. Fabiani M., Ramigni M., Gobbetto V., Mateo-Urdiales A., Pezzotti P., Piovesan C. Vol. 26. 2021. p. 2100420. (Euro Surveill. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region). Italy, 27 December 2020 to 24 March 2021. - PMC - PubMed
    1. Lamb Y.N. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495–501. - PMC - PubMed
    1. Gee J., Marquez P., Su J., Calvert G.M., Liu R., Myers T., et al. First month of COVID-19 vaccine safety monitoring - United States, december 14, 2020-january 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283–288. - PMC - PubMed
    1. Chapin-Bardales J., Myers T., Gee J., Shay D.K., Marquez P., Baggs J., et al. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: findings from the CDC v-safe surveillance system. Vaccine. 2021;39:7066–7073. - PMC - PubMed

Substances